{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:51:05Z","timestamp":1792803065286,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jchf.2025.01.021","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:55:14Z","timestamp":1744815314000},"page":"102415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"13","author":[{"given":"Stavroula","family":"Papapostolou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Iles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Ellims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dion","family":"Stub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jchf.2025.01.021_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.jchf.2025.01.021_bib2","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jchf.2025.01.021_bib3","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/heartjnl-2015-307682","article-title":"Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis","volume":"101","author":"Briasoulis","year":"2015","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12968-019-0561-4","article-title":"The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death","volume":"21","author":"Freitas","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"issue":"4","key":"10.1016\/j.jchf.2025.01.021_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcmg.2011.11.021","article-title":"Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy","volume":"5","author":"Green","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"23","key":"10.1016\/j.jchf.2025.01.021_bib7","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jchf.2025.01.021_bib8","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jchf.2025.01.021_bib9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcmg.2017.04.006","article-title":"Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy","volume":"11","author":"Nakamori","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.jchf.2025.01.021_bib11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jcmg.2022.05.002","article-title":"Myocardial fibrosis assessment using T1 and ECV mapping with histologic validation in chronic dilated cardiomyopathy","volume":"15","author":"Raafs","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.109.854026","article-title":"Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy","volume":"3","author":"Rubinshtein","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.01.021_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1532-429X-14-76","article-title":"Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction","volume":"14","author":"Ellims","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"10.1016\/j.jchf.2025.01.021_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.108.768119","article-title":"Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy","volume":"1","author":"Maron","year":"2008","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jchf.2025.01.021_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/CIRCIMAGING.112.000333","article-title":"T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.jchf.2025.01.021_bib17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jce.12948","article-title":"Diffuse ventricular fibrosis on cardiac magnetic resonance imaging associates with ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"27","author":"McLellan","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jjcc.2014.10.002","article-title":"Increased extent of myocardial fibrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyarrhythmias","volume":"66","author":"Fujita","year":"2015","journal-title":"J Cardiol"},{"issue":"10","key":"10.1016\/j.jchf.2025.01.021_bib19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ehjci\/jeu077","article-title":"A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype","volume":"15","author":"Ellims","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jchf.2025.01.021_bib20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2013.10.084","article-title":"Diffuse myocardial fibrosis evaluated by post-contrast t1 mapping correlates with left ventricular stiffness","volume":"63","author":"Ellims","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5770","key":"10.1016\/j.jchf.2025.01.021_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib23","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"7","key":"10.1016\/j.jchf.2025.01.021_bib24","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/en.2004-0005","article-title":"Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone\/salt-treated rats","volume":"145","author":"Young","year":"2004","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jchf.2025.01.021_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.jchf.2025.01.021_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.jchf.2025.01.021_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"issue":"suppl 1","key":"10.1016\/j.jchf.2025.01.021_bib30","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1186\/1532-429X-15-S1-P3","article-title":"True T1 mapping with SMART1Map (Saturation Method Using Adaptive Recovery Times for Cardiac T1 Mapping): a comparison with MOLLI","volume":"15","author":"Slavin","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.jchf.2025.01.021_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/CIR.0b013e3181e52e69","article-title":"Clinician\u2019s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association","volume":"122","author":"Balady","year":"2010","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jchf.2025.01.021_bib33","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1161\/CIRCULATIONAHA.109.192520","article-title":"Recommendations for clinical exercise laboratories: a scientific statement from the American Heart Association","volume":"119","author":"Myers","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jchf.2025.01.021_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcmg.2012.08.019","article-title":"Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy","volume":"6","author":"Puntmann","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib35","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jchf.2025.01.021_bib36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1046\/j.1440-1681.2001.03586.x","article-title":"Mineralocorticoids and cardiac fibrosis: the decade in review","volume":"28","author":"Funder","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"92","key":"10.1016\/j.jchf.2025.01.021_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.matbio.2020.04.005","article-title":"Targeting the renin-angiotensin-aldosterone system in fibrosis","volume":"91","author":"AlQudah","year":"2020","journal-title":"Matrix Biol"},{"issue":"4","key":"10.1016\/j.jchf.2025.01.021_bib38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11906-013-0354-3","article-title":"Aldosterone mediates cardiac fibrosis in the setting of hypertension","volume":"15","author":"Azibani","year":"2013","journal-title":"Curr Hypertens Rep"},{"issue":"10","key":"10.1016\/j.jchf.2025.01.021_bib39","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000121426.43044.2B","article-title":"Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy","volume":"109","author":"Tsybouleva","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.01.021_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5339\/gcsp.2015.7","article-title":"INHERIT (inhibition of the renin angiotensin system in hypertrophic cardiomyopathy and the effect on hypertrophy\u2014a randomised intervention trial with losartan)","volume":"2015","author":"Olivotto","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12968-016-0267-9","article-title":"Robust free-breathing SASHA T1 mapping with high-contrast image registration","volume":"18","author":"Chow","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.jchf.2025.01.021_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10554-017-1214-z","article-title":"Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance","volume":"34","author":"Maragiannis","year":"2018","journal-title":"Int J Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jchf.2025.01.021_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCIMAGING.108.838367","article-title":"Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo","volume":"2","author":"Moreo","year":"2009","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.jchf.2025.01.021_bib45","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4070\/kcj.2023.0035","article-title":"Prognostic and safety implications of renin-angiotensin-aldosterone system inhibitors in hypertrophic cardiomyopathy: a real-world observation over 2,000 patients","volume":"53","author":"Park","year":"2023","journal-title":"Korean Circ J"},{"issue":"10","key":"10.1016\/j.jchf.2025.01.021_bib46","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1172\/JCI42028","article-title":"Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2","volume":"120","author":"Teekakirikul","year":"2010","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.jchf.2025.01.021_bib47","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jchf.2025.01.021_bib48","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jchf.2025.01.021_bib49","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/jcm13133730","article-title":"Impact of tafamidis on delaying clinical, functional, and structural cardiac changes in patients with wild-type transthyretin amyloid cardiomyopathy","volume":"13","author":"Palmiero","year":"2024","journal-title":"J Clin Med"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792500174X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792500174X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:22:21Z","timestamp":1782966141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221317792500174X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S221317792500174X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.01.021","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"102415"}}